SEC Form 4 · accession 0001209191-15-023195

Regulus Therapeutics Inc. · RGLS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Mar 5, 2015

Accepted (ET)

Mar 5, 2015 · 7:17 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001505512

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 5, 2015	M	89,230	$0.38	A	91,696	D
Common Stock^F2	Mar 5, 2015	S	65,614	$20.0645	D	26,082	D
Common Stock^F3	Mar 5, 2015	S	23,616	$20.8143	D	2,466	D
Common Stock	holding	—	—		—	80,216	I	By the Xanthopoulos Family Trust dated September 30, 2011

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$0.38	Mar 5, 2015	M	89,230	D	—	Feb 8, 2019	Common Stock	89,230	208,287	D

F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted November 25, 2014.
F2The weighted average sale price for the transaction reported was $20.0645, and the range of prices were between $19.50 and $20.50. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F3The weighted average sale price for the transaction reported was $20.8143, and the range of prices were between $20.51 and $21.07. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
F4The shares subject to the option are fully vested.